August 9th 2025
Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.
Pamidronate Relieves Pain, Reduces Analgesic Use in Multiple Myeloma
November 1st 1995LUXEMBOURG-The bisphos-phonate pamidronate (Aredia) not only reduced skeletal morbidity but also relieved pain, reduced analgesic use, and improved quality of life in a multicenter study reported at the 7th International Symposium of the Multinational Association of Supportive Care in Cancer.
Aredia Recommended for New Indication in Multiple Myeloma
September 1st 1995ROCKVILLE, Md--In a move with very little precedent, the FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of a new indication for the bisphosphonate Aredia (pam-idronate disodium for injection) on the basis of a single clinical trial.